Effect of Chronic Incretin-based Therapy in Cystic Fibrosis
Status:
Completed
Trial end date:
2020-03-01
Target enrollment:
Participant gender:
Summary
In recent years, diabetes has emerged as one of the most significant co-diseases that many
Cystic Fibrosis (CF) patients develop. Type 1 and Type 2 diabetes results when either the
body does not make enough insulin or the body does not respond correctly to this insulin.
Insulin is a hormone which is made by cells in the pancreas and helps carry glucose (sugar)
from the food we eat to the cells of the body for energy. While cystic fibrosis related
diabetes (CFRD) has many features similar to both Type 1 and Type 2 diabetes, it is very
different; therefore, treatment and care of CFRD is not the same.
The purpose of this research study is to examine and understand the various mechanisms that
contribute to CFRD and gain a better understanding of potential means to treat CFRD. The
primary objective is to determine effectiveness of chronic incretin-based therapy vs. placebo
on insulin secretion in CF patients with indeterminate glucose tolerance, impaired glucose
tolerance, or CFRD.